Abstract
Effective treatment options for steroid-refractory acute graft-versus-host disease (SR-aGVHD) remain limited. Mesenchymal stromal cells (MSCs) offer a promising therapeutic approach, but the optimal administration protocol is undefined. This retrospective cohort study investigated the impact of MSC infusion frequency on outcomes in patients with grade III–IV SR-aGVHD who received umbilical cord-derived MSCs either once weekly (n = 25) or three times weekly (n = 18). The primary endpoints were overall response rate (ORR) and complete response (CR) at 28 days, and secondary endpoints included overall survival (OS) and changes in lymphocyte subsets. The thrice-weekly group demonstrated significantly superior ORR (77.8% vs. 48.0%, P < 0.05) and CR rates (55.6% vs. 20.0%, P < 0.05), with a particularly notable benefit in gastrointestinal aGVHD (ORR: 73.3% vs. 35.0%, P < 0.05). Immunological analysis showed a more rapid and profound decline in CD3+CD8+ T cells in the thrice-weekly group (nadir: 21.16% vs. 52.09%, P < 0.05; time to nadir: 10 vs. 21 days, P < 0.05). With a median follow-up of 423 days, the thrice-weekly regimen was associated with significantly improved 2-year OS (78.1% vs. 47.4%, P < 0.05). Despite the limitations of a retrospective design, these findings suggest that increased MSC infusion frequency might be associated with improved therapeutic efficacy and survival in severe SR-aGVHD. However, the potential confounding effect of cumulative dose cannot be excluded, and these results warrant validation in prospective randomized trials.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
